Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Who Took Part

In this 52-week, randomized, open-label, parallel-group study, fremanezumab monthly or quarterly was administered in newly enrolled Japanese patients with chronic migraine or episodic migraine.

Safety was assessed by monitoring of treatment-emergent adverse events, including injection-site reactions, laboratory and vital sign assessments.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and parallel-group study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

Everyone knew when CGRP (Calcitonin Gene-Related Peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The CGRP (Calcitonin Gene-Related Peptide) group and the comparison group ran side by side rather than switching.

Newly enrolled patients and rollover patients from previous phase IIb/III trials who did not receive fremanezumab in this study were included in the immunogenicity testing cohort (n = 587).

What Was Measured

The subject headings attached to it are Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Headache, Japan, Migraine Disorders and Outpatients.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Drug safety), a journal based in New Zealand.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.